IS6788A - Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation) - Google Patents

Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)

Info

Publication number
IS6788A
IS6788A IS6788A IS6788A IS6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A
Authority
IS
Iceland
Prior art keywords
isothiazole
carboxamide
proliferation
salts
components
Prior art date
Application number
IS6788A
Other languages
English (en)
Inventor
G. Gant Thomas
Robert Williams Glenn
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6788A publication Critical patent/IS6788A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IS6788A 2000-11-28 2003-04-14 Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation) IS6788A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (1)

Publication Number Publication Date
IS6788A true IS6788A (is) 2003-04-14

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6788A IS6788A (is) 2000-11-28 2003-04-14 Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)

Country Status (50)

Country Link
US (1) US6831091B2 (is)
EP (1) EP1337521B1 (is)
JP (2) JP2004514714A (is)
KR (2) KR20050116401A (is)
CN (1) CN1231474C (is)
AP (1) AP2001002358A0 (is)
AR (1) AR031512A1 (is)
AT (1) ATE340786T1 (is)
AU (2) AU1420402A (is)
BG (1) BG107752A (is)
BR (1) BR0115621A (is)
CA (1) CA2430065C (is)
CR (1) CR6963A (is)
CY (1) CY1106240T1 (is)
CZ (1) CZ20031315A3 (is)
DE (1) DE60123461T2 (is)
DK (1) DK1337521T3 (is)
DO (1) DOP2001000288A (is)
EA (1) EA005859B1 (is)
EC (1) ECSP034628A (is)
EE (1) EE200300247A (is)
ES (1) ES2271086T3 (is)
GE (1) GEP20053652B (is)
GT (1) GT200100237A (is)
HK (1) HK1059085A1 (is)
HN (1) HN2001000268A (is)
HR (1) HRP20030408A2 (is)
HU (1) HUP0302553A3 (is)
IL (1) IL155371A0 (is)
IS (1) IS6788A (is)
MA (1) MA26960A1 (is)
MX (1) MXPA03004714A (is)
MY (1) MY136686A (is)
NO (1) NO325187B1 (is)
NZ (1) NZ525788A (is)
OA (1) OA12532A (is)
PA (1) PA8533801A1 (is)
PE (1) PE20020591A1 (is)
PL (1) PL362079A1 (is)
PT (1) PT1337521E (is)
SI (1) SI1337521T1 (is)
SK (1) SK5862003A3 (is)
SV (1) SV2002000748A (is)
TN (1) TNSN01167A1 (is)
TW (1) TWI287542B (is)
UA (1) UA74221C2 (is)
UY (1) UY27039A1 (is)
WO (1) WO2002044158A1 (is)
YU (1) YU36403A (is)
ZA (1) ZA200303341B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
BR0312798A (pt) * 2002-07-25 2005-05-03 Pfizer Prod Inc Derivados de isotiazol úteis como agentes anticancerìgenos
AP2005003232A0 (en) * 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
RU2317295C1 (ru) * 2003-10-27 2008-02-20 Мерк Энд Ко., Инк. Соль антагониста ccr-2
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SI2044043T2 (sl) 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
CA2806921C (en) 2010-07-23 2019-11-26 Trustees Of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
EP2968650B1 (en) * 2013-03-14 2019-01-16 PanOptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
EP3193867B1 (en) * 2014-09-17 2021-01-20 PanOptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
PA8533801A1 (es) 2002-10-31
HRP20030408A2 (en) 2003-08-31
GEP20053652B (en) 2005-11-10
DK1337521T3 (da) 2007-01-29
PE20020591A1 (es) 2002-07-06
DOP2001000288A (es) 2002-12-15
NO20032388L (no) 2003-07-18
IL155371A0 (en) 2003-11-23
WO2002044158A1 (en) 2002-06-06
MXPA03004714A (es) 2003-08-19
HUP0302553A3 (en) 2009-03-30
CY1106240T1 (el) 2011-06-08
AU1420402A (en) 2002-06-11
BR0115621A (pt) 2003-09-02
NZ525788A (en) 2004-11-26
YU36403A (sh) 2006-08-17
EA005859B1 (ru) 2005-06-30
ECSP034628A (es) 2003-07-25
SV2002000748A (es) 2002-12-02
KR20050116401A (ko) 2005-12-12
PT1337521E (pt) 2006-12-29
JP2008056692A (ja) 2008-03-13
NO20032388D0 (no) 2003-05-27
JP4971946B2 (ja) 2012-07-11
MY136686A (en) 2008-11-28
KR20030059275A (ko) 2003-07-07
HK1059085A1 (en) 2004-06-18
MA26960A1 (fr) 2004-12-20
TWI287542B (en) 2007-10-01
GT200100237A (es) 2002-07-03
DE60123461T2 (de) 2007-02-15
CA2430065C (en) 2008-05-20
SI1337521T1 (sl) 2006-12-31
CR6963A (es) 2003-11-25
HN2001000268A (es) 2002-01-30
CZ20031315A3 (cs) 2004-04-14
CN1231474C (zh) 2005-12-14
NO325187B1 (no) 2008-02-11
EP1337521A1 (en) 2003-08-27
TNSN01167A1 (fr) 2005-11-10
CN1476439A (zh) 2004-02-18
SK5862003A3 (en) 2004-05-04
AR031512A1 (es) 2003-09-24
OA12532A (en) 2006-06-02
UY27039A1 (es) 2002-07-31
HUP0302553A2 (hu) 2003-11-28
AU2002214204B2 (en) 2007-05-24
JP2004514714A (ja) 2004-05-20
CA2430065A1 (en) 2002-06-06
EA200300424A1 (ru) 2003-10-30
UA74221C2 (uk) 2005-11-15
PL362079A1 (en) 2004-10-18
US6831091B2 (en) 2004-12-14
ZA200303341B (en) 2004-04-30
ES2271086T3 (es) 2007-04-16
EP1337521B1 (en) 2006-09-27
ATE340786T1 (de) 2006-10-15
AP2001002358A0 (en) 2001-12-31
EE200300247A (et) 2003-10-15
US20020151573A1 (en) 2002-10-17
DE60123461D1 (de) 2006-11-09
BG107752A (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
IS6788A (is) Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
DE60131315D1 (de) Beatmungskreislauf-Komponenten
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
DK1438306T3 (da) Derivater af UK-2A
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DE60215417D1 (de) Netzwerkschaltung
NO20024355D0 (no) Nukleosidforbindelser og anvendelser derav
IS6000A (is) Ný aralkýlamín af spírófúrópýridínum sem nytsamleg eru í meðferð
DK1542668T3 (da) Formulering af aripiprazolkompleks og fremgangsmåde
DE60220053D1 (de) Schaltkreis
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
IS6786A (is) Samsetning af GABA gerandefnum og sorbitól vetnissviftahindrum
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DE60215601D1 (de) Stabile Zusammensetzung
DE60117938D1 (de) Vorspannen von Bauteilen
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
NO20002091D0 (no) Elektronisk auskultasjons-utstyrssett
IS6620A (is) Nýr fjölgervingur V af tórasemíði
DK1372652T3 (da) Kombination af docetaxel og flavopiridol
FI20011778A (fi) Ryhmälähetyksen toteutus
DK1441746T3 (da) Sammens tning og fremgangsmode